Targeting ribosomes reprograms the tumour microenvironment and augments cancer immunotherapy.

ABSTRACT:

Background

Hyperactive ribosome biogenesis is a hallmark of tumours. Current ribosome-related studies are concentrated on cancer cells. Ribosomes can regulate both tumour and non-cancer cells within the tumour microenvironment, yet the immunomodulatory effects of cellular ribosome biogenesis blockade remain inadequately understood.

Methods

We performed ribosome-targeting therapy utilizing CX-5461, an effective and acknowledged selective inhibitor of ribosome biogenesis, in immunocompetent in vivo models and submitted for single-cell RNA sequencing (scRNA-seq). Additional large-scale human scRNA-seq data, in-house clinical samples and assays were used.

Results

Ribosome inhibition elevated lymphoid cell cytotoxic granule secretion and macrophage pro-inflammation reprogr

SUBMITTER: Cui K 

PROVIDER: S-EPMC12449461 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature